


In conclusion, suppressing the action and/or the activation of MAGL is a promising new therapeutic strategy for the treatment or prevention of neuroinflammation, neurodegenerative diseases, pain, cancer and mental disorders. Furthermore, suppressing the action and/or the activation of MAGL is a promising new therapeutic strategy for providing neuroprotection and myelin regeneration. Accordingly, there is a high unmet medical need for new MAGL inhibitors.


Summary of the Invention

In a first aspect, the present invention discloses provides compounds of Formula (I), or pharmaceutically acceptable salts thereof,



wherein R¹ to R³ are as defined herein.


In one aspect, the present disclosure provides a compound of formula (I)



or a pharmaceutically acceptable salt thereof, wherein:

R¹ is selected from the group consisting of

(i) C₆-C₁₄-aryl optionally substituted with 1-2 substituents independently selected from the group consisting of C₁₋₆-alkoxy, halogen, and a group



(ii) 5- to 6-membered heteroaryl optionally substituted with 1-2 substituents independently selected from the group consisting of halogen, C₁₋₆-alkoxy, C₁₋₆-alkyl, and amino; and

5 (iii) 5- to 14-membered heterocyclyl optionally substituted with 1-3 substituents independently selected from the group consisting of halogen, C₁₋₆-alkyl, and oxo;

R² is selected from the group consisting of

(i) C₁₋₆-alkyl substituted with 1-3 substituents independently selected from halogen;

10 (ii) C₃₋₁₄-cycloalkyl; and

(iii) 5- to 14-membered heteroaryl optionally substituted with 1-3 substituents independently selected from halogen, C₁₋₆-alkyl, halo-C₁₋₆-alkyl, and oxo;

R³ is selected from the group consisting of hydrogen, halogen, C₁₋₆-alkoxy, C₃₋₁₄-cycloalkyloxy, and hydroxy;

15 R⁴ is selected from the group consisting of hydrogen, halogen, C₁₋₆-alkyl, C₁₋₆-alkoxycarbonyl, C₁₋₆-alkoxycarbonyl-NH-, hydroxy, amino, carboxy, C₁₋₆-alkyl-C(O)-NH-, C₂₋₆-alkenyl-C(O)-NH-, carboxy-NH-, oxo, C₃₋₁₄-cycloalkyl, and hydroxy-C₃₋₁₄-cycloalkyl;

L is selected from the group consisting of a covalent bond and -CH=CH-;

20 A is selected from the group consisting of C₆-C₁₄-aryl, 5- to 14-membered heteroaryl, and 5- to 14-membered heterocyclyl; and

n is 1, 2, 3, or 4.

In another aspect, the present disclosure provides a compound, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:

- [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-chloro-3-methoxyphenyl)methanone;
- 5 [(7R,9aS)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-chloro-3-methoxyphenyl)methanone;
- [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(1H-pyrazol-5-yl)phenyl]methanone;
- [(7R,9aS)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-
- 10 2-yl]-[2-chloro-3-(1H-pyrazol-5-yl)phenyl]methanone;
- [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(3-fluoro-1H-pyrazol-4-yl)phenyl]methanone;
- [(7R,9aS)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-
- 2-yl]-[2-chloro-3-(3-fluoro-1H-pyrazol-4-yl)phenyl]methanone;
- 15 [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-chloro-6-methoxypyridin-3-yl)methanone;
- [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-
- 2-yl]-(6-amino-2-methylpyridin-3-yl)methanone;
- [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-
- 20 2-yl]-[2-chloro-3-(3-hydroxyazetidin-1-yl)phenyl]methanone;
- [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-
- 2-yl]-[2-fluoro-3-(3-hydroxyazetidin-1-yl)phenyl]methanone;
- 5-[(7R,9aS)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-
- a]pyrazine-2-carbonyl]-6-chloro-1-methylpyridin-2-one;
- 25 5-[(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-
- a]pyrazine-2-carbonyl]-6-chloro-1-methylpyridin-2-one;
- 3-[3-[(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-
- a]pyrazine-2-carbonyl]-2-chlorophenyl]-1,3-oxazolidin-2-one;

- 1-[3-[(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazine-2-carbonyl]-2-chlorophenyl]imidazolidin-2-one;
[(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-
2-yl]-[2-fluoro-3-(4-methyl-1H-pyrazol-3-yl)phenyl]methanone;
- 5 [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-
2-yl]-[2-chloro-3-(4-methyl-1H-pyrazol-5-yl)phenyl]methanone;
[(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-
2-yl]-[3-(4-methyl-1H-pyrazol-3-yl)phenyl]methanone;
[(7R,9aR)-7-hydroxy-7-[5-(trifluoromethyl)pyridin-2-yl]-3,4,6,8,9,9a-hexahydro-1H-
- 10 pyrido[1,2-a]pyrazin-2-yl]-(2-chloro-3-methoxyphenyl)methanone;
[(7S,9aS)-7-hydroxy-7-[5-(trifluoromethyl)pyridin-2-yl]-3,4,6,8,9,9a-hexahydro-1H-
pyrido[1,2-a]pyrazin-2-yl]-(2-chloro-3-methoxyphenyl)methanone;
[(7R,9aR)-7-hydroxy-7-[5-(trifluoromethyl)pyridin-2-yl]-3,4,6,8,9,9a-hexahydro-1H-
pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(1H-pyrazol-5-yl)phenyl]methanone;
- 15 [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-
2-yl]-(2-fluoro-3-morpholin-4-yl)phenyl]methanone;
tert-butyl 4-[3-[(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-
pyrido[1,2-a]pyrazine-2-carbonyl]-2-fluorophenyl]piperazine-1-carboxylate;
[(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-
- 20 2-yl]-(2-fluoro-3-piperazin-1-yl)phenyl]methanone;
(2-chloro-3-methoxyphenyl)-[rac-(7R,9aS)-7-hydroxy-7-(2-methylpropyl)-3,4,6,8,9,9a-
hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]methanone;
(2-chloro-3-methoxyphenyl)-[rac-(7R,9aS)-7-cyclopentyl-7-hydroxy-3,4,6,8,9,9a-
hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]methanone;
- 25 (2-chloro-3-methoxyphenyl)-[rac-(7R,9aR)-7-hydroxy-7-(trifluoromethyl)-3,4,6,8,9,9a-
hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]methanone;
[(7R,9aR)-7-(4-chlorophenyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]-[2-
bromo-3-[(Z)-2-phenylethenyl]phenyl]methanone;

- [(7R,9aR)-7-(4-chlorophenyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]-[2-bromo-3-[(E)-2-phenylethenyl]phenyl]methanone;
tert-butylN-[4-[(E)-2-[3-[(7R,9aR)-7-(4-chlorophenyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazine-2-carbonyl]-2-bromophenyl]ethenyl]phenyl]carbamate;
- 5 N-[4-[(E)-2-[3-[(7R,9aR)-7-(4-chlorophenyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazine-2-carbonyl]-2-bromophenyl]ethenyl]phenyl]prop-2-enamide;
4-[(E)-2-[3-[(7R,9aR)-7-(4-chlorophenyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazine-2-carbonyl]-2-bromo-phenyl]vinyl]-N-methyl-benzamide;
[(7R,9aR)-7-hydroxy-7-[5-(trifluoromethyl)pyridin-2-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(3-hydroxyazetidin-1-yl)phenyl]methanone;
- 10 [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-chloro-3-hydroxyphenyl)methanone;
4-(3-[(7S,9aR)-7-(4-chlorophenyl)-7-hydroxyoctahydro-2H-pyrido[1,2-a]pyrazine-2-carbonyl]-2-fluorophenyl)piperazin-2-one;
- 15 4-[3-[(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazine-2-carbonyl]-2-chlorophenyl]piperazin-2-one;
[(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(6-oxa-1-azaspiro[3.3]heptan-1-yl)phenyl]methanone;
[(7S,9aS)-7-hydroxy-7-[5-(trifluoromethyl)pyridin-2-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(difluoromethoxy)phenyl]methanone;
- 20 [(7R,9aR)-7-hydroxy-7-[5-(trifluoromethyl)pyridin-2-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(difluoromethoxy)phenyl]methanone;
[(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-fluoro-3-(3-hydroxyazetidin-1-yl)phenyl]methanone;
- 25 [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(3-hydroxyazetidin-1-yl)phenyl]methanone;
[(7R,9aR)-7-hydroxy-7-[5-(trifluoromethyl)pyridin-2-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-chloro-3-fluorophenyl)methanone;

- [(7S,9aS)-7-hydroxy-7-[5-(trifluoromethyl)pyridin-2-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-chloro-3-fluorophenyl)methanone;
- [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-[(3S)-3-hydroxypyrrolidin-1-yl]phenyl]methanone;
- 5 [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-[(3R)-3-hydroxypyrrolidin-1-yl]phenyl]methanone;
- [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-[(3R)-3-hydroxypyrrolidin-1-yl]phenyl]methanone;
- [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(3-hydroxy-3-methylazetidin-1-yl)phenyl]methanone;
- 10 [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-[(3S)-3-hydroxypiperidin-1-yl]phenyl]methanone;
- [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-[(3R)-3-hydroxypiperidin-1-yl]phenyl]methanone;
- 15 [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(4-hydroxypiperidin-1-yl)phenyl]methanone;
- [2-chloro-3-(3-hydroxy-3-methylpyrrolidin-1-yl)phenyl]-[rac-(7R,9aS)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]methanone;
- 20 [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-[(3S,4S)-3,4-dihydroxypyrrolidin-1-yl]phenyl]methanone;
- [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-[3-fluoro-3-(hydroxymethyl)azetidin-1-yl]phenyl]methanone;
- [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-[3-(hydroxymethyl)azetidin-1-yl]phenyl]methanone;
- 25 [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(1H-pyrazol-3-yl)phenyl]methanone;
- [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-fluoro-3-(1H-pyrazol-3-yl)phenyl]methanone;

- [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-fluoro-3-(1,2-thiazol-3-yl)phenyl]methanone;
- [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(4-fluoro-1H-pyrazol-5-yl)phenyl]methanone;
- 5 [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(1,2,4-thiadiazol-3-yl)phenyl]methanone;
- [(7S,9aR)-7-(3,4-difluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-chloro-3-methoxyphenyl)methanone;
- [(7R,9aS)-7-(3,4-difluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-
- 10 a]pyrazin-2-yl]-(2-chloro-3-methoxyphenyl)methanone;
- [(7S,9aR)-7-(3,4-difluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-fluoro-3-(1H-pyrazol-5-yl)phenyl]methanone;
- [(7S,9aR)-7-(3,4-difluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-
- a]pyrazin-2-yl]-[2-fluoro-3-(4-fluoro-1H-pyrazol-5-yl)phenyl]methanone;
- 15 [(7S,9aR)-7-(3,4-difluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-
- a]pyrazin-2-yl]-[2-chloro-3-(3-hydroxyazetidin-1-yl)phenyl]methanone;
- [(7R,9aR)-7-hydroxy-7-[5-(trifluoromethyl)pyridin-2-yl]-3,4,6,8,9,9a-hexahydro-1H-
- pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(4-fluoro-1H-pyrazol-5-yl)phenyl]methanone;
- [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-
- 20 a]pyrazin-2-yl]-(2,3-dihydro-1H-indol-4-yl)methanone;
- [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-
- 2-yl]-[4-chloro-5-(1H-pyrazol-3-yl)pyridin-3-yl]methanone;
- [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-
- 2-yl]-[2-chloro-3-(1,2-thiazol-3-yl)phenyl]methanone;
- 25 [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-
- 2-yl]-[2-chloro-3-(1,2-thiazol-4-yl)phenyl]methanone;
- [(7R,9aR)-7-hydroxy-7-[5-(trifluoromethyl)pyridin-2-yl]-3,4,6,8,9,9a-hexahydro-1H-
- pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(1,2-thiazol-3-yl)phenyl]methanone;


[(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[4-methyl-5-(1H-pyrazol-3-yl)pyridin-3-yl]methanone;

(2-chloro-3-methoxyphenyl)-[rac-(7R,9aS)-7-hydroxy-7-[6-(trifluoromethyl)pyridin-3-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]methanone; and


5 (2-chloro-3-methoxyphenyl)-[rac-(7R,9aR)-7-hydroxy-7-[6-(trifluoromethyl)pyridin-3-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]methanone.

In a further aspect, the ~~The~~ present ~~invention~~disclosure provides a process of manufacturing the compounds of formula (I) as described herein, comprising:

- 10 (a) reacting an amine **12** or **14**, wherein R² is as defined herein and R³ is hydroxy (**12**) or hydrogen (**14**)



with a carboxylic acid **15**, wherein R¹ is as defined herein



15 in the presence of a coupling reagent, such as HATU, DCC, EDCI, HOBt, TBTU or T₃P, and a base, such as Huenig's base, triethyl amine or DMAP, to afford said compound of formula (I) wherein R³ is hydroxy or hydrogen; and optionally, provided R³ is hydroxy;

- (b) alkylating the alcohol R^3 by treating it with an appropriate base, such as NaH, KH, NaHMDS, LiHMDS or LDA, preferably with NaH, followed by addition of an electrophile, e.g. an alkyl- or cycloalkyl halide, such as MeI, EtI, *i*PrI or CyPrI to yield the corresponding compound of formula (I), wherein R^3 is alkoxy or cycloalkyloxy; or
- (c) transforming the alcohol R^3 into a halogen by reacting the compound of formula (I) wherein R^3 is hydroxy with (i) an acid, e.g. HCl, HBr, HI, POCl₃, SOCl₂ or PBr₃; or (ii) with a suitable amino sulfurane reagent such as DAST; or (iii) a sulfonylating reagent such as mesyl chloride, followed by reacting the intermediate sulfonate ester with a halogenide, e.g. NaF to yield the corresponding compound of formula (I), wherein R^3 is halogen.

~~In a further aspect, the~~The present ~~invention~~disclosure provides a compound of formula (I) as described herein, when manufactured according to the processes described herein.

In a further aspect, the present ~~invention~~disclosure provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, for use as therapeutically active substance.

In a further aspect, the present ~~invention~~disclosure provides a pharmaceutical composition comprising a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, and a therapeutically inert carrier.

~~In a further aspect, the~~The present ~~invention~~disclosure provides the use of a compound of formula (I) as described herein, or of a pharmaceutically acceptable salt thereof, for inhibiting monoacylglycerol lipase (MAGL) in a mammal.

~~In a further aspect, the~~The present ~~invention~~disclosure provides the use of a compound of formula (I) as described herein, or of a pharmaceutically acceptable salt thereof, for the treatment or prophylaxis of neuroinflammation, neurodegenerative diseases, pain, cancer and/or mental disorders in a mammal.

~~In a further aspect, the~~The present ~~invention~~disclosure provides the use of a compound of formula (I) as described herein, or of a pharmaceutically acceptable salt thereof, for the treatment or prophylaxis of multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine,

depression, hepatocellular carcinoma, colon carcinogenesis, ovarian cancer, neuropathic pain, chemotherapy induced neuropathy, acute pain, chronic pain and/or spasticity associated with pain in a mammal.

~~In a further aspect, the~~The present ~~invention~~disclosure provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, for use in a method of inhibiting monoacylglycerol lipase in a mammal.

In a further aspect, the present ~~invention~~disclosure provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, for use in the treatment or prophylaxis of neuroinflammation, neurodegenerative diseases, pain, cancer and/or mental disorders in a mammal.

In a further aspect, the present ~~invention~~disclosure provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, for use in the treatment or prophylaxis of multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon carcinogenesis, ovarian cancer, neuropathic pain, chemotherapy induced neuropathy, acute pain, chronic pain and/or spasticity associated with pain in a mammal.

~~In a further aspect, the~~The present ~~invention~~disclosure provides the use of a compound of formula (I) as described herein, or of a pharmaceutically acceptable salt thereof, for the preparation of a medicament for inhibiting monoacylglycerol lipase in a mammal.

~~In a further aspect, the~~The present ~~invention~~disclosure provides the use of a compound of formula (I) as described herein, or of a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment or prophylaxis of neuroinflammation, neurodegenerative diseases, pain, cancer and/or mental disorders in a mammal. In a further aspect, the present disclosure provides use of a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for the treatment or prophylaxis of neuroinflammation, neurodegenerative diseases, pain, cancer and/or mental disorders in a mammal.

~~In a further aspect, the~~The present ~~invention~~disclosure provides the use of a compound of formula (I) as described herein, or of a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment or prophylaxis of multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain
5 injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon

carcinogenesis, ovarian cancer, neuropathic pain, chemotherapy induced neuropathy, acute pain, chronic pain and/or spasticity associated with pain in a mammal. In a further aspect, the present disclosure provides use of a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for the treatment or prophylaxis of multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon carcinogenesis, ovarian cancer, neuropathic pain, chemotherapy induced neuropathy, acute pain, chronic pain and/or spasticity associated with pain in a mammal.

10 ~~In a further aspect, the~~ The present ~~invention~~ disclosure provides a method for inhibiting monoacylglycerol lipase in a mammal, which method comprises administering an effective amount of a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, to the mammal.

15 ~~In a further aspect, the~~ The present ~~invention~~ disclosure provides a method for the treatment or prophylaxis of neuroinflammation, neurodegenerative diseases, pain, cancer and/or mental disorders in a mammal, which method comprises administering an effective amount of a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, to the mammal.

20 ~~In a further aspect, the~~ The present ~~invention~~ disclosure provides a method for the treatment or prophylaxis of multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon carcinogenesis, ovarian cancer, neuropathic pain, chemotherapy induced neuropathy, acute pain, chronic pain and/or spasticity associated with pain in a mammal, which method comprises
25 administering an effective amount of a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, to the mammal.


Detailed Description of the Invention

Definitions

Features, integers, characteristics, compounds, chemical moieties or groups described in conjunction with a particular aspect, embodiment or example of the invention are to be
5 understood to be applicable to any other aspect, embodiment or example described herein, unless incompatible therewith. All of the features disclosed in this specification (including

CLAIMS


1. A compound of formula (I)



or a pharmaceutically acceptable salt thereof, wherein:

5 R^1 is selected from the group consisting of

(i) C_6 - C_{14} -aryl optionally substituted with 1-2 substituents independently selected from the group consisting of C_{1-6} -alkoxy, halogen, and a group



10 (ii) 5- to 6-membered heteroaryl optionally substituted with 1-2 substituents independently selected from the group consisting of halogen, C_{1-6} -alkoxy, C_{1-6} -alkyl, and amino; and

(iii) 5- to 14-membered heterocyclyl optionally substituted with 1-3 substituents independently selected from the group consisting of halogen, C_{1-6} -alkyl, and oxo;

15 R^2 is selected from the group consisting of

(i) C_{1-6} -alkyl substituted with 1-3 substituents independently selected from halogen;

(ii) C_{3-14} -cycloalkyl; and

20 (iii) 5- to 14-membered heteroaryl optionally substituted with 1-3 substituents independently selected from halogen, C_{1-6} -alkyl, halo- C_{1-6} -alkyl, and oxo;

R^3 is selected from the group consisting of hydrogen, halogen, C_{1-6} -alkoxy, C_{3-14} -cycloalkyloxy, and hydroxy;

25 R^4 is selected from the group consisting of hydrogen, halogen, C_{1-6} -alkyl, C_{1-6} -alkoxycarbonyl, C_{1-6} -alkoxycarbonyl-NH-, hydroxy, amino, carboxy, C_{1-6} -alkyl-C(O)-NH-, C_{2-6} -alkenyl-C(O)-NH-, carboxy-NH-, oxo, C_{3-14} -cycloalkyl, and hydroxy- C_{3-14} -cycloalkyl;


L is selected from the group consisting of a covalent bond and $-\text{CH}=\text{CH}-$;

A is selected from the group consisting of C₆-C₁₄-aryl, 5- to 14-membered heteroaryl, and 5- to 14-membered heterocyclyl; and
n is 1, 2, 3, or 4.

2. The compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, wherein:

R¹ is selected from the group consisting of

(i) C₆-C₁₄-aryl substituted with 1-2 substituents independently selected from the



group consisting of C₁₋₆-alkoxy, halogen, and a group ;

(ii) 5- to 6-membered heteroaryl optionally substituted with 1-2 substituents


independently selected from the group consisting of halogen, C₁₋₆-alkoxy, C₁₋₆-alkyl, and amino; and

(iii) 5- to 14-membered heterocyclyl optionally substituted with 1-3 substituents independently selected from the group consisting of halogen, C₁₋₆-alkyl, and oxo;

R⁴ is selected from the group consisting of hydrogen, halogen, C₁₋₆-alkyl, C₁₋₆-alkoxycarbonyl, C₁₋₆-alkoxycarbonyl-NH-, hydroxy and oxo; and
n is 1 or 2.

3. The compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, wherein:

R¹ is C₆-C₁₄-aryl substituted with 1-2 substituents independently selected from the



group consisting of C₁₋₆-alkoxy, halogen, and a group ;

R⁴ is selected from the group consisting of hydrogen, halogen, and hydroxy;


L is a covalent bond;

A is selected from the group consisting of 5- to 14-membered heteroaryl and 5- to 14-membered heterocyclyl; and

n is 1 or 2.

4. The compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, wherein:

R^1 is phenyl substituted with 1-2 substituents independently selected from the



5 group consisting of chloro, fluoro, methoxy and a group

R^4 is selected from the group consisting of hydrogen, fluoro, and hydroxy;

L is a covalent bond;

A is selected from the group consisting of pyrazolyl and azetidiny; and

n is 1 or 2.

- 10 5. The compound of formula (I) according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein R^2 is selected from the group consisting of

(i) C_{1-6} -alkyl substituted with 1-3 substituents independently selected from halogen;

15 (ii) C_{3-14} -cycloalkyl; and

(iii) 5- to 14-membered heteroaryl substituted with halo- C_{1-6} -alkyl.


6. The compound of formula (I) according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein R^2 is 5- to 14-membered heteroaryl substituted with halo- C_{1-6} -alkyl.

- 20 7. The compound of formula (I) according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein R^2 is pyridyl substituted with CF_3 .

8. The compound of formula (I) according to any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, wherein R^3 is hydrogen or hydroxy.

- 25 9. The compound of formula (I) according to any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, wherein R^3 is hydroxy.

10. —The compound of formula (I) according to any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, wherein R^4 is selected from the group consisting of hydrogen, halogen, C_{1-6} -alkyl, C_{1-6} -alkoxycarbonyl, C_{1-6} -alkoxycarbonyl-NH-, hydroxy and oxo.
- 5 11. —The compound of formula (I) according to any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, wherein R^4 is selected from the group consisting of hydrogen, halogen, and hydroxy.
12. —The compound of formula (I) according to any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, wherein R^4 is selected from the group
- 10 consisting of hydrogen, fluoro, and hydroxy.
13. —The compound of formula (I) according to any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, wherein L is a covalent bond.
14. —The compound of formula (I) according to any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof, wherein A is selected from the group
- 15 consisting of 5- to 14-membered heteroaryl and 5- to 14-membered heterocyclyl.
15. —The compound of formula (I) according to any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof, wherein A is selected from the group consisting of pyrazolyl and azetidiny.
16. —The compound of formula (I) according to any one of claims 1 to 15, or a pharmaceutically acceptable salt thereof, wherein n is 1 or 2.
- 20 17. —The compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, wherein:
- R^1 —is selected from the group consisting of
- (i) — C_6 - C_{14} -aryl substituted with 1-2 substituents independently selected from
- 25 the group consisting of C_{1-6} -alkoxy, halogen, and a group



- (ii) ~~5 to 6 membered heteroaryl substituted with 1-2 substituents independently selected from the group consisting of halogen, C₁₋₆-alkoxy, C₁₋₆-alkyl, and amino; and~~
- (iii) ~~5 to 14 membered heterocyclyl optionally substituted with 1-3 substituents independently selected from the group consisting of halogen, C₁₋₆-alkyl, and oxo;~~
- R^2 ~~is selected from the group consisting of~~
- (i) ~~C₁₋₆-alkyl substituted with 1-3 substituents independently selected from halogen;~~
- (ii) ~~C₃₋₁₄-cycloalkyl; and~~
- (iii) ~~5 to 14 membered heteroaryl substituted with halo-C₁₋₆-alkyl;~~
- R^3 ~~is hydrogen or hydroxy;~~
- R^4 ~~is selected from the group consisting of hydrogen, halogen, C₁₋₆-alkyl, C₁₋₆-alkoxycarbonyl, C₁₋₆-alkoxycarbonyl-NH-, hydroxy and oxo;~~
- L ~~is selected from the group consisting of a covalent bond and -CH=CH-;~~
- A ~~is selected from the group consisting of C₆-C₁₄-aryl, 5 to 14 membered heteroaryl, and 5 to 14 membered heterocyclyl; and~~
- n ~~is 1 or 2.~~

18. ~~The compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, wherein:~~

R^1 ~~is C₆-C₁₄-aryl substituted with 1-2 substituents independently selected from the~~



R^2 ~~is 5 to 14 membered heteroaryl substituted with halo-C₁₋₆-alkyl;~~

R^3 ~~is hydroxy;~~

R^4 ~~is selected from the group consisting of hydrogen, halogen, and hydroxy;~~


L ~~is a covalent bond;~~

A ~~is selected from the group consisting of 5 to 14 membered heteroaryl, and 5 to 14 membered heterocyclyl; and~~

n ~~is 1 or 2.~~

19. The compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, wherein:

R^1 is phenyl substituted with 1-2 substituents independently selected from the



group consisting of chloro, fluoro, methoxy, and a group

;

R^2 is pyridyl substituted with CF_3 ;

R^3 is hydroxy;


R^4 is selected from the group consisting of hydrogen, fluoro, and hydroxy;

L is a covalent bond;

A is selected from the group consisting of pyrazolyl and azetidyl; and

n is 1 or 2.


20. A compound of formula (I)



or a pharmaceutically acceptable salt thereof, wherein:

R^1 is selected from the group consisting of

(i) C_6 - C_{14} -aryl optionally substituted with 1-2 substituents independently selected from the group consisting of C_{1-6} -alkoxy, halogen, and a group



;

(ii) 5- to 6-membered heteroaryl optionally substituted with 1-2 substituents independently selected from the group consisting of halogen, C_{1-6} -

alkoxy, C_{1-6} -alkyl, and amino; and


(iii) 5- to 14-membered heterocyclyl optionally substituted with 1-3 substituents independently selected from the group consisting of halogen, C_{1-6} -alkyl, and oxo;

R^2 is selected from the group consisting of

(i) C_{1-6} -alkyl optionally substituted with 1-3 substituents independently selected from halogen;

- (ii) ~~C₃₋₁₄-cycloalkyl;~~
 (iii) ~~C₆-C₁₄-aryl optionally substituted with 1-2 substituents independently selected from halogen;~~
 (iv) ~~5 to 14-membered heteroaryl optionally substituted with 1-3 substituents independently selected from halogen, C₁₋₆-alkyl, halo-C₁₋₆-alkyl, and oxo; and~~
 (v) ~~5 to 14-membered heterocyclyl optionally substituted with 1-3 substituents independently selected from halogen, C₁₋₆-alkyl, halo-C₁₋₆-alkyl, and oxo;~~
~~R³ is selected from the group consisting of hydrogen, halogen, C₁₋₆-alkoxy, C₃₋₁₄-cycloalkyloxy, and hydroxy;~~
~~R⁴ is selected from the group consisting of C₁₋₆-alkoxycarbonyl-NH-, hydroxy, hydroxy-C₁₋₆-alkyl and C₂₋₆-alkenyl C(O)-NH-;~~
~~L is selected from the group consisting of a covalent bond and -CH=CH-;~~
~~A is selected from the group consisting of C₆-C₁₄-aryl, 5 to 14-membered heteroaryl, and 5 to 14-membered heterocyclyl; and~~
~~n is 1, 2, 3, or 4.~~


21. The compound of formula (I) according to claim 20, or a pharmaceutically acceptable salt thereof, wherein R¹ is selected from the group consisting of
- (i) ~~C₆-C₁₄-aryl substituted with 1-2 substituents independently selected from the~~




- ~~group consisting of C₁₋₆-alkoxy, halogen, and a group~~ ;
- (ii) ~~5 to 6-membered heteroaryl optionally substituted with 1-2 substituents independently selected from the group consisting of halogen, C₁₋₆-alkoxy, C₁₋₆-alkyl, and amino; and~~
- (iii) ~~5 to 14-membered heterocyclyl optionally substituted with 1-3 substituents independently selected from the group consisting of halogen, C₁₋₆-alkyl, and oxo.~~

22. The compound of formula (I) according to claim 20, or a pharmaceutically acceptable salt thereof, wherein R¹ is ~~C₆-C₁₄-aryl substituted with 1-2 substituents~~

~~independently selected from the group consisting of C₁₋₆-alkoxy, halogen, and a~~



23. ~~The compound of formula (I) according to claim 20, or a pharmaceutically acceptable salt thereof, wherein R¹ is phenyl substituted with 1-2 substituents independently selected from the group consisting of chloro, fluoro, methoxy and a~~



24. ~~The compound of formula (I) according to any one of claims 20 to 23, or a pharmaceutically acceptable salt thereof, wherein R² is selected from the group consisting of~~

- ~~(i) — C₁₋₆-alkyl optionally substituted with 1-3 substituents independently selected from halogen;~~
- ~~(ii) — C₃₋₁₄-cycloalkyl;~~
- ~~(iii) — C₆-C₁₄-aryl substituted with 1-2 substituents independently selected from halogen; and~~
- ~~(iv) — 5- to 14-membered heteroaryl substituted with halo-C₁₋₆-alkyl.~~

25. ~~The compound of formula (I) according to any one of claims 20 to 23, or a pharmaceutically acceptable salt thereof, wherein R² is selected from the group consisting of~~

- ~~(i) — halo-C₆-C₁₄-aryl; and~~
- ~~(ii) — 5- to 14-membered heteroaryl substituted with halo-C₁₋₆-alkyl.~~

26. ~~The compound of formula (I) according to any one of claims 20 to 23, or a pharmaceutically acceptable salt thereof, wherein R² is selected from the group consisting of~~

- ~~(i) — chlorophenyl; and~~
- ~~(ii) — pyridyl substituted with CF₃.~~

27. ~~The compound of formula (I) according to any one of claims 20 to 26, or a pharmaceutically acceptable salt thereof, wherein R³ is hydrogen or hydroxy.~~

28. —The compound of formula (I) according to any one of claims 20 to 26, or a pharmaceutically acceptable salt thereof, wherein R^3 is hydroxy.

29. —The compound of formula (I) according to any one of claims 20 to 28, or a pharmaceutically acceptable salt thereof, wherein R^4 is selected from the group consisting of C_{1-6} -alkoxycarbonyl NH-, hydroxy, and C_{2-6} -alkenyl C(O)-NH-.

30. —The compound of formula (I) according to any one of claims 20 to 28, or a pharmaceutically acceptable salt thereof, wherein R^4 is hydroxy.

31. —The compound of formula (I) according to any one of claims 20 to 30, or a pharmaceutically acceptable salt thereof, wherein L is a covalent bond.

32. —The compound of formula (I) according to any one of claims 20 to 31, or a pharmaceutically acceptable salt thereof, wherein A is selected from the group consisting of 5- to 14-membered heteroaryl and 5- to 14-membered heterocyclyl.


33. —The compound of formula (I) according to any one of claims 20 to 31, or a pharmaceutically acceptable salt thereof, wherein A is selected from the group consisting of pyrazolyl and azetidiny.

34. —The compound of formula (I) according to any one of claims 20 to 31, or a pharmaceutically acceptable salt thereof, wherein n is 1 or 2.

35. —The compound of formula (I) according to claim 20, or a pharmaceutically acceptable salt thereof, wherein:

R^1 —is selected from the group consisting of

(i) — C_6 - C_{14} -aryl substituted with 1-2 substituents independently selected from the group consisting of C_{1-6} -alkoxy, halogen, and a group



(ii) —5- to 6-membered heteroaryl substituted with 1-2 substituents independently selected from the group consisting of halogen, C_{1-6} -alkoxy, C_{1-6} -alkyl, and amino; and

(iii) ~~5- to 14-membered heterocyclyl optionally substituted with 1-3 substituents independently selected from the group consisting of halogen, C₁₋₆-alkyl, and oxo;~~

~~R²—is selected from the group consisting of~~

5 ~~(i) —C₁₋₆-alkyl optionally substituted with 1-3 substituents independently selected from halogen;~~

~~(ii) —C₃₋₁₄-cycloalkyl;~~

~~(iii) —C₆-C₁₄-aryl substituted with 1-2 substituents independently selected from halogen; and~~

10 ~~(iv) —5- to 14-membered heteroaryl substituted with halo-C₁₋₆-alkyl;~~

~~R³—is hydrogen or hydroxy;~~

~~R⁴—is selected from the group consisting of C₁₋₆-alkoxycarbonyl-NH-, C₂₋₆-alkenyl-C(O)-NH-, and hydroxy;~~


~~L— is selected from the group consisting of a covalent bond and —CH=CH—;~~

15 ~~A— is selected from the group consisting of C₆-C₁₄-aryl, 5- to 14-membered heteroaryl, and 5- to 14-membered heterocyclyl; and~~

~~n— is 1 or 2.~~

36.—The compound of formula (I) according to claim 20, or a pharmaceutically acceptable salt thereof, wherein:

20 ~~R¹— is C₆-C₁₄-aryl substituted with 1-2 substituents independently selected from the~~



~~group consisting of C₁₋₆-alkoxy, halogen, and a group~~

;

~~R²—is selected from the group consisting of~~

~~(i) —halo-C₆-C₁₄-aryl; and~~

~~(ii) —5- to 14-membered heteroaryl substituted with halo-C₁₋₆-alkyl;~~

25 ~~R³—is hydroxy;~~

~~R⁴—is hydroxy;~~


~~L— is a covalent bond;~~

~~A— is selected from the group consisting of 5- to 14-membered heteroaryl, and 5- to 14-membered heterocyclyl; and~~

30 ~~n— is 1 or 2.~~

37. The compound of formula (I) according to claim 20, or a pharmaceutically acceptable salt thereof, wherein:

R^1 is phenyl substituted with 1-2 substituents independently selected from the



group consisting of chloro, fluoro, methoxy, and a group

;

R^2 is selected from the group consisting of

(i) chlorophenyl; and

(ii) pyridyl substituted with CF_3 ;

R^3 is hydroxy;

R^4 is hydroxy;

L is a covalent bond;

A is selected from the group consisting of pyrazolyl and azetidiny; and

n is 1 or 2.

10. A compound, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:

[(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-chloro-3-methoxyphenyl)methanone;

[(7R,9aS)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-chloro-3-methoxyphenyl)methanone;

[(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(1H-pyrazol-5-yl)phenyl]methanone;

[(7R,9aS)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(1H-pyrazol-5-yl)phenyl]methanone;

[(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(3-fluoro-1H-pyrazol-4-yl)phenyl]methanone;

[(7R,9aS)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(3-fluoro-1H-pyrazol-4-yl)phenyl]methanone;

[(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-chloro-6-methoxypyridin-3-yl)methanone;

[(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(6-amino-2-methylpyridin-3-yl)methanone;

[(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(3-hydroxyazetidin-1-yl)phenyl]methanone;

- [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-fluoro-3-(3-hydroxyazetidin-1-yl)phenyl]methanone;
5-[(7R,9aS)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazine-2-carbonyl]-6-chloro-1-methylpyridin-2-one;
5 5-[(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazine-2-carbonyl]-6-chloro-1-methylpyridin-2-one;
3-[3-[(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazine-2-carbonyl]-2-chlorophenyl]-1,3-oxazolidin-2-one;
1-[3-[(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazine-2-carbonyl]-2-chlorophenyl]imidazolidin-2-one;
10 [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-fluoro-3-(4-methyl-1H-pyrazol-3-yl)phenyl]methanone;
[(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(4-methyl-1H-pyrazol-5-yl)phenyl]methanone;
15 [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[3-(4-methyl-1H-pyrazol-3-yl)phenyl]methanone;
[(7R,9aR)-7-hydroxy-7-[5-(trifluoromethyl)pyridin-2-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-chloro-3-methoxyphenyl)methanone;
[(7S,9aS)-7-hydroxy-7-[5-(trifluoromethyl)pyridin-2-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-chloro-3-methoxyphenyl)methanone;
20 [(7R,9aR)-7-hydroxy-7-[5-(trifluoromethyl)pyridin-2-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(1H-pyrazol-5-yl)phenyl]methanone;
[(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-fluoro-3-morpholin-4-ylphenyl)methanone;
25 tert-butyl 4-[3-[(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazine-2-carbonyl]-2-fluorophenyl]piperazine-1-carboxylate;
[(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-fluoro-3-piperazin-1-ylphenyl)methanone;
(2-chloro-3-methoxyphenyl)-[rac-(7R,9aS)-7-hydroxy-7-(2-methylpropyl)-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]methanone;
30 (2-chloro-3-methoxyphenyl)-[rac-(7R,9aS)-7-cyclopentyl-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]methanone;
(2-chloro-3-methoxyphenyl)-[rac-(7R,9aR)-7-hydroxy-7-(trifluoromethyl)-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]methanone;
35 [(7R,9aR)-7-(4-chlorophenyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]-[2-bromo-3-[(Z)-2-phenylethenyl]phenyl]methanone;

- [(7R,9aR)-7-(4-chlorophenyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]-
[2-bromo-3-[(E)-2-phenylethenyl]phenyl]methanone;
tert-butylN-[4-[(E)-2-[3-[(7R,9aR)-7-(4-chlorophenyl)-1,3,4,6,7,8,9,9a-
octahydropyrido[1,2-a]pyrazine-2-carbonyl]-2-
5 bromophenyl]ethenyl]phenyl]carbamate;
N-[4-[(E)-2-[3-[(7R,9aR)-7-(4-chlorophenyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-
a]pyrazine-2-carbonyl]-2-bromophenyl]ethenyl]phenyl]prop-2-enamide;
4-[(E)-2-[3-[(7R,9aR)-7-(4-chlorophenyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-
a]pyrazine-2-carbonyl]-2-bromo-phenyl]vinyl]-N-methyl-benzamide;
- 10 [(7R,9aR)-7-hydroxy-7-[5-(trifluoromethyl)pyridin-2-yl]-3,4,6,8,9,9a-hexahydro-
1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(3-hydroxyazetidin-1-
yl)]phenyl]methanone;
[(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-
a]pyrazin-2-yl]-(2-chloro-3-hydroxyphenyl)methanone;
15 4-(3-[(7S,9aR)-7-(4-chlorophenyl)-7-hydroxyoctahydro-2H-pyrido[1,2-a]pyrazine-
2-carbonyl)-2-fluorophenyl]piperazin-2-one;
4-[3-[(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-
pyrido[1,2-a]pyrazine-2-carbonyl]-2-chlorophenyl]piperazin-2-one;
[(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-
20 a]pyrazin-2-yl]-[2-chloro-3-(6-oxa-1-azaspiro[3.3]heptan-1-yl)]phenyl]methanone;
[(7S,9aS)-7-hydroxy-7-[5-(trifluoromethyl)pyridin-2-yl]-3,4,6,8,9,9a-hexahydro-1H-
pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(difluoromethoxy)phenyl]methanone;
[(7R,9aR)-7-hydroxy-7-[5-(trifluoromethyl)pyridin-2-yl]-3,4,6,8,9,9a-hexahydro-
1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(difluoromethoxy)phenyl]methanone;
25 [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-
pyrido[1,2-a]pyrazin-2-yl]-[2-fluoro-3-(3-hydroxyazetidin-1-yl)]phenyl]methanone;
[(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-
pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(3-hydroxyazetidin-1-yl)]phenyl]methanone;
[(7R,9aR)-7-hydroxy-7-[5-(trifluoromethyl)pyridin-2-yl]-3,4,6,8,9,9a-hexahydro-
30 1H-pyrido[1,2-a]pyrazin-2-yl]-(2-chloro-3-fluorophenyl)methanone;
[(7S,9aS)-7-hydroxy-7-[5-(trifluoromethyl)pyridin-2-yl]-3,4,6,8,9,9a-hexahydro-1H-
pyrido[1,2-a]pyrazin-2-yl]-(2-chloro-3-fluorophenyl)methanone;
[(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-
pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-[(3S)-3-hydroxypyrrolidin-1-
35 yl]]phenyl]methanone;

- [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-[(3R)-3-hydroxypyrrolidin-1-yl]phenyl]methanone;
- 5 [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-[(3R)-3-hydroxypyrrolidin-1-yl]phenyl]methanone;
[(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(3-hydroxy-3-methylazetidin-1-yl)phenyl]methanone;
[(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-[(3S)-3-hydroxypiperidin-1-
- 10 yl]phenyl]methanone;
[(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-[(3R)-3-hydroxypiperidin-1-
yl]phenyl]methanone;
[(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-
- 15 a]pyrazin-2-yl]-[2-chloro-3-(4-hydroxypiperidin-1-yl)phenyl]methanone;
[2-chloro-3-(3-hydroxy-3-methylpyrrolidin-1-yl)phenyl]-[rac-(7R,9aS)-7-(4-
chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-
yl]methanone;
[(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-
- 20 pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-[(3S,4S)-3,4-dihydroxypyrrolidin-1-
yl]phenyl]methanone;
[(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-
pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-[3-fluoro-3-(hydroxymethyl)azetidin-1-
- 25 yl]phenyl]methanone;
[(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-
pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-[3-(hydroxymethyl)azetidin-1-
yl]phenyl]methanone;
[(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-
- 30 pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(1H-pyrazol-3-yl)phenyl]methanone;
[(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-
pyrido[1,2-a]pyrazin-2-yl]-[2-fluoro-3-(1H-pyrazol-3-yl)phenyl]methanone;
[(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-
a]pyrazin-2-yl]-[2-fluoro-3-(1,2-thiazol-3-yl)phenyl]methanone;
[(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-
- 35 pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(4-fluoro-1H-pyrazol-5-
yl)phenyl]methanone;

[(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(1,2,4-thiadiazol-3-yl)phenyl]methanone;
[(7S,9aR)-7-(3,4-difluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-chloro-3-methoxyphenyl)methanone;
5 [(7R,9aS)-7-(3,4-difluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-chloro-3-methoxyphenyl)methanone;
[(7S,9aR)-7-(3,4-difluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-fluoro-3-(1H-pyrazol-5-yl)phenyl]methanone;
[(7S,9aR)-7-(3,4-difluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-fluoro-3-(4-fluoro-1H-pyrazol-5-yl)phenyl]methanone;
10 [(7S,9aR)-7-(3,4-difluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(3-hydroxyazetidin-1-yl)phenyl]methanone;
[(7R,9aR)-7-hydroxy-7-[5-(trifluoromethyl)pyridin-2-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(4-fluoro-1H-pyrazol-5-yl)phenyl]methanone;
15 [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2,3-dihydro-1H-indol-4-yl)methanone;
[(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[4-chloro-5-(1H-pyrazol-3-yl)pyridin-3-yl]methanone;
20 [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(1,2-thiazol-3-yl)phenyl]methanone;
[(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(1,2-thiazol-4-yl)phenyl]methanone;
[(7R,9aR)-7-hydroxy-7-[5-(trifluoromethyl)pyridin-2-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(1,2-thiazol-3-yl)phenyl]methanone;
25 [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[4-methyl-5-(1H-pyrazol-3-yl)pyridin-3-yl]methanone;
(2-chloro-3-methoxyphenyl)-[rac-(7R,9aS)-7-hydroxy-7-[6-(trifluoromethyl)pyridin-3-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]methanone; and
30 (2-chloro-3-methoxyphenyl)-[rac-(7R,9aR)-7-hydroxy-7-[6-(trifluoromethyl)pyridin-3-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]methanone.

38.11. A-The compound according to claim 10, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:

35 [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-chloro-3-methoxyphenyl)methanone;

- [(7R,9aS)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-chloro-3-methoxyphenyl)methanone;
- [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(1H-pyrazol-5-yl)phenyl]methanone;
- 5 [(7R,9aS)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(1H-pyrazol-5-yl)phenyl]methanone;
- [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(3-fluoro-1H-pyrazol-4-yl)phenyl]methanone;
- [(7R,9aS)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(3-fluoro-1H-pyrazol-4-yl)phenyl]methanone;
- 10 [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-chloro-6-methoxypyridin-3-yl)methanone;
- [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(6-amino-2-methylpyridin-3-yl)methanone;
- 15 [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(3-hydroxyazetidin-1-yl)phenyl]methanone;
- [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-fluoro-3-(3-hydroxyazetidin-1-yl)phenyl]methanone;
- 5-[(7R,9aS)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazine-2-carbonyl]-6-chloro-1-methylpyridin-2-one;
- 20 5-[(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazine-2-carbonyl]-6-chloro-1-methylpyridin-2-one;
- 3-[3-[(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazine-2-carbonyl]-2-chlorophenyl]-1,3-oxazolidin-2-one;
- 25 1-[3-[(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazine-2-carbonyl]-2-chlorophenyl]imidazolidin-2-one;
- [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-fluoro-3-(4-methyl-1H-pyrazol-3-yl)phenyl]methanone;
- [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(4-methyl-1H-pyrazol-5-yl)phenyl]methanone;
- 30 [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[3-(4-methyl-1H-pyrazol-3-yl)phenyl]methanone;

[(7R,9aR)-7-hydroxy-7-[5-(trifluoromethyl)pyridin-2-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-chloro-3-methoxyphenyl)methanone;
 [(7S,9aS)-7-hydroxy-7-[5-(trifluoromethyl)pyridin-2-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-chloro-3-methoxyphenyl)methanone;
 5 [(7R,9aR)-7-hydroxy-7-[5-(trifluoromethyl)pyridin-2-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(1H-pyrazol-5-yl)phenyl]methanone;
 [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-fluoro-3-morpholin-4-ylphenyl)methanone;
 tert-butyl 4-[3-[(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazine-2-carbonyl]-2-fluorophenyl]piperazine-1-carboxylate;
 10 [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-fluoro-3-piperazin-1-ylphenyl)methanone;
 (2-chloro-3-methoxyphenyl)-[rac-(7R,9aS)-7-hydroxy-7-(2-methylpropyl)-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]methanone;
 15 (2-chloro-3-methoxyphenyl)-[rac-(7R,9aS)-7-cyclopentyl-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]methanone;
 (2-chloro-3-methoxyphenyl)-[rac-(7R,9aR)-7-hydroxy-7-(trifluoromethyl)-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]methanone;
 [(7R,9aR)-7-(4-chlorophenyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]-[2-bromo-3-[(Z)-2-phenylethenyl]phenyl]methanone;
 20 [(7R,9aR)-7-(4-chlorophenyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]-[2-bromo-3-[(E)-2-phenylethenyl]phenyl]methanone;
 tert-butyl N-[4-[(E)-2-[3-[(7R,9aR)-7-(4-chlorophenyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazine-2-carbonyl]-2-bromophenyl]ethenyl]phenyl]carbamate;
 25 N-[4-[(E)-2-[3-[(7R,9aR)-7-(4-chlorophenyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazine-2-carbonyl]-2-bromophenyl]ethenyl]phenyl]prop-2-enamide; and
 4-[(E)-2-[3-[(7R,9aR)-7-(4-chlorophenyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazine-2-carbonyl]-2-bromo-phenyl]vinyl]-N-methyl-benzamide.

30 [39:12.](#) **A-The** compound [according to claim 10](#), or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:

- [(7R,9aR)-7-hydroxy-7-[5-(trifluoromethyl)pyridin-2-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(3-hydroxyazetidin-1-yl)phenyl]methanone;
- 5 [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-chloro-3-hydroxyphenyl)methanone;
- 4-3-((7S,9aR)-7-(4-chlorophenyl)-7-hydroxyoctahydro-2H-pyrido[1,2-a]pyrazine-2-carbonyl)-2-fluorophenyl)piperazin-2-one;
- 4-[3-[(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazine-2-carbonyl]-2-chlorophenyl]piperazin-2-one;
- 10 [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(6-oxa-1-azaspiro[3.3]heptan-1-yl)phenyl]methanone;
- [(7S,9aS)-7-hydroxy-7-[5-(trifluoromethyl)pyridin-2-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(difluoromethoxy)phenyl]methanone;
- 15 [(7R,9aR)-7-hydroxy-7-[5-(trifluoromethyl)pyridin-2-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(difluoromethoxy)phenyl]methanone;
- [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-fluoro-3-(3-hydroxyazetidin-1-yl)phenyl]methanone;
- 20 [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(3-hydroxyazetidin-1-yl)phenyl]methanone;
- [(7R,9aR)-7-hydroxy-7-[5-(trifluoromethyl)pyridin-2-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-chloro-3-fluorophenyl)methanone;
- 25 [(7S,9aS)-7-hydroxy-7-[5-(trifluoromethyl)pyridin-2-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-chloro-3-fluorophenyl)methanone;
- [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-[(3S)-3-hydroxypyrrolidin-1-yl]phenyl]methanone;
- 30 [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-[(3R)-3-hydroxypyrrolidin-1-yl]phenyl]methanone;

- [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-[(3R)-3-hydroxypyrrolidin-1-yl]phenyl]methanone;
- [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(3-hydroxy-3-methylazetidin-1-yl)phenyl]methanone;
- [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-[(3S)-3-hydroxypiperidin-1-yl]phenyl]methanone;
- [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-[(3R)-3-hydroxypiperidin-1-yl]phenyl]methanone;
- [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(4-hydroxypiperidin-1-yl)phenyl]methanone;
- [2-chloro-3-(3-hydroxy-3-methylpyrrolidin-1-yl)phenyl]-[rac-(7R,9aS)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]methanone;
- [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-[(3S,4S)-3,4-dihydroxypyrrolidin-1-yl]phenyl]methanone;
- [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-[3-fluoro-3-(hydroxymethyl)azetidin-1-yl]phenyl]methanone;
- [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-[3-(hydroxymethyl)azetidin-1-yl]phenyl]methanone;
- [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(1H-pyrazol-3-yl)phenyl]methanone;
- [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-fluoro-3-(1H-pyrazol-3-yl)phenyl]methanone;
- [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-fluoro-3-(1,2-thiazol-3-yl)phenyl]methanone;

- [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(4-fluoro-1H-pyrazol-5-yl)phenyl]methanone;
- 5 [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(1,2,4-thiadiazol-3-yl)phenyl]methanone;
- [(7S,9aR)-7-(3,4-difluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-chloro-3-methoxyphenyl)methanone;
- [(7R,9aS)-7-(3,4-difluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-chloro-3-methoxyphenyl)methanone;
- 10 [(7S,9aR)-7-(3,4-difluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-fluoro-3-(1H-pyrazol-5-yl)phenyl]methanone;
- [(7S,9aR)-7-(3,4-difluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-fluoro-3-(4-fluoro-1H-pyrazol-5-yl)phenyl]methanone;
- [(7S,9aR)-7-(3,4-difluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(3-hydroxyazetidin-1-yl)phenyl]methanone;
- 15 [(7R,9aR)-7-hydroxy-7-[5-(trifluoromethyl)pyridin-2-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(4-fluoro-1H-pyrazol-5-yl)phenyl]methanone;
- [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2,3-dihydro-1H-indol-4-yl)methanone;
- 20 [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[4-chloro-5-(1H-pyrazol-3-yl)pyridin-3-yl]methanone;
- [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(1,2-thiazol-3-yl)phenyl]methanone;
- 25 [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(1,2-thiazol-4-yl)phenyl]methanone;
- [(7R,9aR)-7-hydroxy-7-[5-(trifluoromethyl)pyridin-2-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(1,2-thiazol-3-yl)phenyl]methanone;
- [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[4-methyl-5-(1H-pyrazol-3-yl)pyridin-3-yl]methanone;
- 30 (2-chloro-3-methoxyphenyl)-[rac-(7R,9aS)-7-hydroxy-7-[6-(trifluoromethyl)pyridin-3-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]methanone; and

(2-chloro-3-methoxyphenyl)-[rac-(7R,9aR)-7-hydroxy-7-[6-(trifluoromethyl)pyridin-3-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]methanone.

13. The compound according to claim 12, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:

[(7R,9aR)-7-hydroxy-7-[5-(trifluoromethyl)pyridin-2-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(3-hydroxyazetidin-1-yl)phenyl]methanone;

[(7S,9aS)-7-hydroxy-7-[5-(trifluoromethyl)pyridin-2-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(difluoromethoxy)phenyl]methanone;

[(7R,9aR)-7-hydroxy-7-[5-(trifluoromethyl)pyridin-2-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(difluoromethoxy)phenyl]methanone;

[(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-fluoro-3-(3-hydroxyazetidin-1-yl)phenyl]methanone;

[(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(3-hydroxyazetidin-1-yl)phenyl]methanone;

[(7R,9aR)-7-hydroxy-7-[5-(trifluoromethyl)pyridin-2-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-chloro-3-fluorophenyl)methanone;

[(7S,9aS)-7-hydroxy-7-[5-(trifluoromethyl)pyridin-2-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-chloro-3-fluorophenyl)methanone;

[(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-[(3S)-3-hydroxypyrrolidin-1-yl]phenyl]methanone;

[(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-[(3R)-3-hydroxypyrrolidin-1-yl]phenyl]methanone;


[(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-[(3R)-3-hydroxypyrrolidin-1-yl]phenyl]methanone;

[(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(3-hydroxy-3-methylazetidin-1-yl)phenyl]methanone;

- [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-[(3S)-3-hydroxypiperidin-1-yl]phenyl]methanone;
- 5 [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-[(3R)-3-hydroxypiperidin-1-yl]phenyl]methanone;
- [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(4-hydroxypiperidin-1-yl)phenyl]methanone;
- 10 [2-chloro-3-(3-hydroxy-3-methylpyrrolidin-1-yl)phenyl]-[rac-(7R,9aS)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]methanone;
- [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-[(3S,4S)-3,4-dihydroxypyrrolidin-1-yl]phenyl]methanone;
- 15 [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-[3-fluoro-3-(hydroxymethyl)azetidin-1-yl]phenyl]methanone;
- [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-[3-(hydroxymethyl)azetidin-1-yl]phenyl]methanone;
- 20 [(7S,9aR)-7-(3,4-difluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(3-hydroxyazetidin-1-yl)phenyl]methanone;
- [(7R,9aR)-7-hydroxy-7-[5-(trifluoromethyl)pyridin-2-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(4-fluoro-1H-pyrazol-5-yl)phenyl]methanone;
- 25 [(7R,9aR)-7-hydroxy-7-[5-(trifluoromethyl)pyridin-2-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(1,2-thiazol-3-yl)phenyl]methanone;
- (2-chloro-3-methoxyphenyl)-[rac-(7R,9aS)-7-hydroxy-7-[6-(trifluoromethyl)pyridin-3-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]methanone; and
- 30 (2-chloro-3-methoxyphenyl)-[rac-(7R,9aR)-7-hydroxy-7-[6-(trifluoromethyl)pyridin-3-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]methanone.


~~40. A process of manufacturing the compounds of formula (I) according to any one of claims 1 to 39, or pharmaceutically acceptable salts thereof, comprising:~~

~~a) reacting an amine **12** or **14**, wherein R^2 is as defined in claim 1 or 20 and R^3 is hydroxy (**12**) or hydrogen (**14**)~~



5

~~with a carboxylic acid **15**, wherein R^1 is as defined in claim 1~~



10

~~in the presence of a coupling reagent and a base to afford said compound of formula (I) wherein R^3 is hydroxy or hydrogen; and optionally, provided R^3 is hydroxy;~~

~~b) alkylating the alcohol R^3 by treating it with a base followed by addition of a suitable electrophile to yield the corresponding compound of formula (I), wherein R^3 is alkoxy or cycloalkyloxy; or~~

15

~~c) transforming the alcohol R^3 into a halogen by reacting the compound of formula (I) wherein R^3 is hydroxy with (i) a halogenating reagent; or (ii) a sulfonylating reagent, followed by reacting the intermediate sulfonate ester with a halogenide; to yield the corresponding compound of formula (I), wherein R^3 is halogen.~~

20

~~41. A compound of formula (I) according to any one of claims 1 to 39, or a pharmaceutically acceptable salt thereof, when manufactured according to the process of claim 40.~~

42.14. A compound of formula (I) according to any one of claims 1 to ~~39 and 41~~13, or a pharmaceutically acceptable salt thereof, for use as therapeutically active substance.

43.15. A pharmaceutical composition comprising a compound of formula (I) according to any one of claims 1 to ~~39 and 41~~13, or a pharmaceutically acceptable salt thereof, and a therapeutically inert carrier.

~~44. The use of a compound of formula (I) according to any one of claims 1 to 39 and 41, or a pharmaceutically acceptable salt thereof, for the treatment or prophylaxis of neuroinflammation, neurodegenerative diseases, pain, cancer and/or mental disorders in a mammal.~~

~~45. The use of a compound of formula (I) according to any one of claims 1 to 39 and 41, or a pharmaceutically acceptable salt thereof, for the treatment or prophylaxis of multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon carcinogenesis, ovarian cancer, neuropathic pain, chemotherapy induced neuropathy, acute pain, chronic pain and/or spasticity associated with pain in a mammal.~~

46.16. A compound of formula (I) according to any one of claims 1 to ~~39 and 41~~13, or a pharmaceutically acceptable salt thereof, for use in the treatment or prophylaxis of neuroinflammation, neurodegenerative diseases, pain, cancer and/or mental disorders in a mammal.

47.17. A compound of formula (I) according to any one of claims 1 to ~~39 and 41~~13, or a pharmaceutically acceptable salt thereof, for use in the treatment or prophylaxis of multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon carcinogenesis, ovarian cancer, neuropathic pain, chemotherapy induced neuropathy, acute pain, chronic pain and/or spasticity associated with pain in a mammal.

48.18. ~~The use~~Use of a compound of formula (I) according to any one of claims 1 to ~~39 and 41~~13, or a pharmaceutically acceptable salt thereof, ~~for in~~ the preparation of a medicament for the treatment or prophylaxis of neuroinflammation, neurodegenerative diseases, pain, cancer and/or mental disorders in a mammal.

49.19. ~~The use~~Use of a compound of formula (I) according to any one of claims 1 to 39 and 41-13, or a pharmaceutically acceptable salt thereof, ~~for in~~ the preparation of a medicament for the treatment or prophylaxis of multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon carcinogenesis, ovarian cancer, neuropathic pain, chemotherapy induced neuropathy, acute pain, chronic pain and/or spasticity associated with pain in a mammal.

~~50.—A method for the treatment or prophylaxis of neuroinflammation, neurodegenerative diseases, pain, cancer and/or mental disorders in a mammal, which method comprises administering an effective amount of a compound of formula (I) according to any one of claims 1 to 39 and 41, or a pharmaceutically acceptable salt thereof, to the mammal.~~

~~51.—A method for the treatment or prophylaxis of multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon carcinogenesis, ovarian cancer, neuropathic pain, chemotherapy induced neuropathy, acute pain, chronic pain and/or spasticity associated with pain in a mammal, which method comprises administering an effective amount of a compound of formula (I) according to any one of claims 1 to 39 and 41, or a pharmaceutically acceptable salt thereof, to the mammal.~~